Mayo Clinic Studying Genomics of Antiplatelet Heart Medication
Two-year study of Plavix and Brilinta to include approximately 5,300 patients from 15 hospitals worldwide; participant DNA biobank to help elucidate genomics of coronary artery disease ROCHESTER, Minn. — Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The [...] (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - November 13, 2013 Category: Hospital Management Source Type: news
Diabetes & CAD; Clopidogrel Genotyping; Testosterone TherapyDiabetes & CAD; Clopidogrel Genotyping; Testosterone Therapy
Join us for a comprehensive review of this week's most important cardiology news. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 8, 2013 Category: Consumer Health News Tags: Cardiology Blog Source Type: news
Clopidogrel Genotyping in Primary PCI: A Cautious AdvanceClopidogrel Genotyping in Primary PCI: A Cautious Advance
In a rare clinical trial, genotyping for clopidogrel loss of function seemed to guide antiplatelet changes when they were most needed; but was it the genotyping assay that made the difference? Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Genetic profiling identifies heart attack patients resistant to blood thinners
Results of the GIANT trial reported at TCT 2013 According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel. Findings from the GIANT trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Results of the GIANT trial reported at TCT 2013
(Cardiovascular Research Foundation) According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2013 Category: Global & Universal Source Type: news
Massive DAPT Study Sees Early Geographic SignalsMassive DAPT Study Sees Early Geographic Signals
Results for the 26 000-patient trial comparing 12 vs 30 months of aspirin plus clopidogrel or prasugrel are due out in 2014, but early insights are worth keeping an eye on, one investigator says. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Clopidogrel Plus Aspirin Promising in Stroke PreventionClopidogrel Plus Aspirin Promising in Stroke Prevention
For preventing stroke after TIA, are 2 drugs better than 1? Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news
Clue to unlocking the mystery of life-saving heart drug offered by lung infections
Scientists from the University of Sheffield have discovered ground breaking clues as to how the pioneering heart drug ticagrelor might reduce the risk of dying following a heart attack, in comparison to previous standard treatments. The new findings, published in Platelets, show that ticagrelor may reduce the risk of dying as a result of a lung infection after suffering a heart attack compared to patients treated with the drug clopidogrel... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 16, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Clopidogrel Contribution to Fracture Risk in Stroke 'Minor'Clopidogrel Contribution to Fracture Risk in Stroke 'Minor'
The increased fracture risk associated with the stroke itself far exceeds that associated with clopidogrel, new research indicates. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Ticagrelor and Outcomes for Patients With Prior CABGTicagrelor and Outcomes for Patients With Prior CABG
Patients with prior CABG who present with acute coronary syndromes have a high risk for recurrent events. Is intensive antiplatelet therapy with ticagrelor beneficial in this setting -- when compared with clopidogrel? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Double vs Triple Therapy With PCIDouble vs Triple Therapy With PCI
This F1000 commentary reports on a study comparing clopidogrel therapy with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention. Faculty of 1000 (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 24, 2013 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news
New pooled analysis shows cangrelor demonstrates reduction in angiographic complications compared to oral clopidogrel
The Medicines Company (NASDAQ: MDCO) reported presentation and publication of a pooled analysis of three Phase III clinical trials of an investigational intravenous (IV) antiplatelet, cangrelor. The trials compared IV cangrelor to either oral clopidogrel or placebo for prevention of thrombotic (clotting) complications during and after percutaneous coronary intervention (PCI). The findings of the pooled CHAMPION program confirm the results of the CHAMPION PHOENIX trial presented and published in April 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
ARCTIC-GENE Strikes Against Genotype-Guided AntiplateletsARCTIC-GENE Strikes Against Genotype-Guided Antiplatelets
It's an inspired idea that isn't panning out, at least based on the genetic substudy of a trial looking at platelet-monitoring-guided therapy in coronary stenting: patients with a slow-clopidogrel-metabolization genotype had poorer clopidogrel responses, but therapy adjustments based on that information didn't help clinically. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
ARCTIC-GENE throws cold water on genotype-guided antiplatelet therapy at PCI
It's an inspired idea that isn't panning out, at least based on the genetic substudy of a trial looking at platelet-monitoring-guided therapy in coronary stenting: patients with a slow-clopidogrel-metabolization genotype had poorer clopidogrel responses, but therapy adjustments based on that information didn't help clinically. (Source: theHeart.org)
Source: theHeart.org - September 4, 2013 Category: Cardiology Source Type: news
